One of the first targeted treatments for schizophrenia has been announced in this month's American Journal of Psychiatry. The new drug, currently referred to as experimental compound MK-0777, targets working memory problems.
Working memory refers to a temporary storage and processing system. It is an active system in the sense that information stays in memory only so long as the person is consciously manipulating or processing it. Any deficit in working memory can have a profound effect on pe...
Read more »...approval by the FDA for the use of Risperdal in the treatment of schizophrenia and bipolar... Read more »
...after an individual begins undergoing treatment for schizophrenia? What are some common side... Read more »
...Abilify (aripiprazole) was approved by the FDA for the treatment of schizophrenia in the... Read more »
Recently, I was reviewing the literature on tardive dyskinesia, and it struck me how frustrating it... Read more »
There's some good news for people diagnosed with schizophrenia. The National Institute on Mental... Read more »
The U.S. Food and Drug Administration has approved Risperdal for the treatment of schizophrenia and bipolar disorder in children and teens. Risperdal... Read summary »
By Lucy Williams, Ivanhoe Health Correspondent ORLANDO, Fla. (Ivanhoe Newswire) -- Some patients undergoing treatment for mental illness gain so... Read summary »
The Food and Drug Administration (FDA) has approved extended-release Invega for the treatment of schizophrenia. The FDA made the decision after... Read summary »
Drugmaker AstraZeneca is seeking approval from the Food and Drug Administration for a once-daily formula of Seroquel. Seroquel is currently approved... Read summary »
A study suggests that immaturity in the areas of the brain that control memory and mood may lead to schizophrenia. In a study involving mice that... Read summary »